Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of metformin administration and exercise
PACTR202203690920424Completed
- Sponsor
- Faculty of Medicine of Sousse
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of metformin in cardiometabolic risk (CMR) (3 arms), sponsored by Faculty of Medicine of Sousse. Primary endpoint: Postprandial triglycerides. Started Feb 2022; status: completed.
02
Drugs
metformin
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on PACTR202203690920424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203690920424.